Pfizer announced this week that it has received FDA approval to enroll children as young as 12 years old in its COVID-19 vaccine trial. The expansion is aimed at understanding whether the vaccine would be safe and effective for adolescents.
Until now, children under 16 have not been included in any of the COVID-19 vaccine trials in the U.S., and the average age of participants has skewed much older.
” I think this is a really big deal,” says L.J. Tan, chief strategy officer of the Immunization Action Coalition. “Without clinical trials actually done in children, the only way to actually extend the use of the COVID-19 vaccine into children would be to rely on the adult data,” Tan says, which is not ideal.
Earlier this month, the American Academy of Pediatricians wrote to top federal health officials urging them to take this step. “Children must be included in vaccine trials to best understand any potential unique immune responses and/or unique safety concerns,” wrote AAP president Sara Goza in a letter, which was sent to Alex Azar, Secretary of the U.S. Department of Health and Human Services, and Stephen Hahn, Commissioner of the U.S. Food and Drug Administration.
In recent months, it’s become increasingly clear that children can be infected with the virus, and while they often have only mild disease or are asymptomatic, they can also infect others.
Goza wrote that more than half a million children have been infected with COVID-19 this year. “More than two-thirds of the children who died were Black and Latinx children,”
Given that children have been greatly affected by the pandemic it is unethical, “to allow children to take on great burdens during this pandemic but not have the opportunity to benefit from a vaccine, or to delay that benefit for an extended period of time, because they have not been included in vaccine trials”.
In an updated statement on its website, Pfizer outlined the change to include children. Last month, the company said it would expand its trial to include teenagers 16 and older. Now, the company says it has received permission from the FDA to enroll children aged 12 and older. “By doing so, we will be able to better understand the potential safety and efficacy of the vaccine in individuals from more ages and backgrounds,” the statement says.
Pediatricians and infectious disease experts say it made sense to start the vaccine trials with older participants who have a higher risk of more serious illness from COVID-19.
“Children have not been the main focus at this point because of the rush to get these trials going in adults,” says infectious disease expert Yvonne Maldonado, a professor of pediatrics, epidemiology and population health at Stanford University, who chairs the AAP committee on infectious diseases.
